Caribou Biosciences to evaluate strategic alternatives
CRBU•Caribou Biosciences will evaluate strategic alternatives, discontinue its vispa-cel and CB-011 CAR-T therapy programs, and implement workforce and cost reductions; it reported $113.8 million in cash and securities as of June 30, 2026.
1. Company plans changes
Caribou Biosciences said it will evaluate strategic alternatives and discontinue its vispa-cel and CB-011 CAR-T cell therapy programs. It plans substantial workforce reductions, expected to be mostly complete in the fourth quarter of 2026, and reported $113.8 million in cash and securities as of June 30, 2026.
